Intranasal Palivizumab Fails to Prevent RSV Infection in Preterm Babies
A recent double-blind, randomized placebo-controlled trial found that daily intranasal palivizumab, a mucosal monoclonal antibody (mAb) did not prevent Respiratory Syncytial Virus (RSV) infection in late preterm infants. The findings were published in eClinicalMedicine of Lancet. A total of 268 infants were enrolled from January 14, 2019 to January 28, 2021, with half receiving intranasal […]